Objective To determine whether anxiety and depression are associated with cognition in multiple sclerosis (MS), and whether these associations are similar in other immune-mediated inflammatory diseases (IMID; including inflammatory bowel disease [IBD] and rheumatoid arthritis [RA]) and in anxious/depressed individuals (ANX/DEP) without an IMID.
Multiple sclerosis (MS) is an immune-mediated inflammatory disease (IMID) of the CNS that shares features of inflammation and immune system dysregulation with other chronic diseases, such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), that affect different organ systems. Like MS, IBD and RA also share an increased prevalence of depression and anxiety as compared to the general population. [1] [2] [3] Cognitive impairment is common in MS, affecting an estimated 40%-70% of individuals 4 ; deficits in information processing speed are most often identified. 5 Several studies suggest that comorbidities, 6 including depression and anxiety, influence physical impairment in MS. 7 Prior studies also suggest that depression influences cognition in MS, although findings have been inconsistent. 8, 9 While recent studies have suggested that anxiety is associated with impaired information processing speed in MS, 10 few have jointly assessed the effects of depression and anxiety on cognition in MS. 5 Moreover, it is uncertain whether the nature and magnitude of the effects of depression and anxiety on cognition in MS are the same as observed in other IMID without direct CNS involvement, [11] [12] [13] or the same as for persons with depression and anxiety without an IMID.
14 Such knowledge is of interest given the potential role of inflammation in psychiatric disorders including depression and anxiety. 15 We aimed to examine the association of anxiety and depression on cognitive function in MS, and to determine whether the effects of anxiety and depression on cognition in MS were similar to those observed in IBD and RA, and in individuals with anxiety and depressive disorders (ANX/ DEP) without an IMID. We hypothesized that those with MS, IBD, or RA who reported symptoms of anxiety and depression would exhibit greater cognitive impairments than those without such symptoms. We also hypothesized that such impairments would be more common in an IMID cohort with comorbid anxiety and depression than in a non-IMID cohort living with anxiety and depression.
Glossary ANCOVA = analysis of covariance; ANOVA = analysis of variance; ANX/DEP = individuals with anxiety and depressive disorders; CVLT-II = California Verbal Learning Test, Second Edition; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; HADS = Hospital Anxiety and Depression Scale; HADS-A = Hospital Anxiety and Depression Scale-anxiety; HADS-D = Hospital Anxiety and Depression Scale-depression; IBD = inflammatory bowel disease; IMID = immune-mediated inflammatory disease; LNS = Letter Number Sequencing; MANOVA = multivariate analysis of variance; MDD = major depressive disorder; MS = multiple sclerosis; RA = rheumatoid arthritis; SCID-IV = Structured Clinical Interview for DSM-IV; SDMT = Symbol Digit Modalities Test; WTAR = Wechsler Test of Adult Reading.
Methods

Participants
As described elsewhere, 4 cohorts of participants from Manitoba, Canada, were enrolled in a longitudinal study of the effects of comorbid anxiety and depression in IMID. 16 Individuals were eligible to participate if, in their lifetime, they had had any of the following: (1) definite MS, 17 (2) definite IBD-including Crohn disease or ulcerative colitis, 18 (3) definite RA, 19 or (4) major depressive disorder (MDD) or any diagnosed anxiety disorder or both (ANX/DEP group). 20 Diagnoses of MS, IBD, and RA were confirmed by medical records review. Current or lifetime diagnoses of MDD or an anxiety disorder were confirmed by the Structured Clinical Interview for DSM-IV (SCID-IV), 20 since DSM-IV was in widespread use at the time of study inception. Posttraumatic stress disorder and obsessivecompulsive disorder were included as anxiety disorders as per the DSM-IV classification. Participants were required to be aged ≥18 years and able to provide informed consent. Participants were recruited through multiple methods: general community announcements (i.e., posters), approaching patients during or before their scheduled medical clinic visits, and contacting patients via established registries/clinic mailing lists. 16 Standard protocol approvals, registrations, and patient consents The study was approved by the University of Manitoba Health Research Ethics Board. All participants provided written informed consent.
Measures
Questionnaires captured sociodemographic characteristics including sex, date of birth, race, and total years of formal education. Participants completed questionnaires and cognitive testing on the day of enrollment. Structured psychiatric interviews were completed the same day for 37.4% of participants, within 1 week of enrollment for 97.8%, and within 2 weeks for the remainder.
We assigned diagnoses of MDD or an anxiety disorder using the SCID-IV 20 in all participants. Although individuals without IMID were included in the ANX/DEP group if they had MDD or any diagnosed anxiety disorder in their lifetime, for these analyses, we considered only current diagnoses of MDD and any anxiety disorder. The lone exception to this was the exclusion of specific phobias that have not been found to influence cognition as much as other psychiatric disorders. 21 Per the DSM-IV, current MDD and obsessive-compulsive disorder were defined as occurring over the last 2 weeks; posttraumatic stress disorder and panic disorder were classified as current if occurring in the last month; generalized anxiety disorder and social phobia were classified as current if symptoms persisted over the last 6 months.
Severity of current symptoms of depression and anxiety was determined via the Hospital Anxiety and Depression Scale (HADS), 22 a 14-item questionnaire that assesses symptoms of depression (HADS-D) and anxiety (HADS-A) in the last week. Total scores range from 0 to 21 on each scale. The HADS has been validated for use in MS, IBD, RA, and the general population. [23] [24] [25] [26] Three neuropsychological tests were selected to broadly assess core domains of cognitive functioning: the California Verbal Learning Test, Second Edition (CVLT-II), 27 Letter Number Sequencing (LNS) from the Wechsler Memory Scale, Third Edition, 28 and the Symbol Digit Modalities Test (SDMT). 29 The CVLT-II assesses the capacity to learn and remember verbal information, the LNS assesses working memory capacity, and the SDMT assesses processing speed. These measures were chosen to assess cognitive domains commonly reported as affected in those with MS, IBD, RA, 4, [30] [31] [32] and anxiety and depression disorders. 21 The Wechsler Test of Adult Reading (WTAR) 33 was included to estimate premorbid (i.e., relatively resistant to brain disease) cognitive functioning, based on single word reading.
Cognitive test scores were divided into 4 cognitive domains of interest. Raw scores in processing speed (SDMT), verbal learning (CVLT-II trials 1-5), and delayed recall memory (CVLT-II long-delay free-recall trial) were converted to z scores using regression-based norms adjusted for age, sex, and years of education. 34 As regression-based norms were not available, raw scores for working memory (LNS) were converted to z scores based on normative data controlling for age. 28 Participants were classified as unimpaired or impaired (i.e., z of −1.5 or lower) 35 on each domain. Raw scores for estimated premorbid IQ (WTAR) were converted to standard scores adjusting for age and years of education. 33 
Analysis
To examine the effect of clinically meaningful symptoms of anxiety or depression on cognitive functioning, participants within each disease cohort were dichotomized based on their self-reported symptoms of anxiety (HADS-A score) and of depression (HADS-D score) (i.e., ≥11 vs <11). We chose this threshold based on several considerations. First, the initial publication of the HADS proposed that scores of 8-10 indicated possible anxiety or depression, while scores ≥11 indicated probable anxiety or depression. 22 Second, although an initial validation study suggested that a cutpoint of 8 was optimal for the HADS in MS, 36 more recent studies have suggested that scores ≥9-11 would be optimal, particularly for the HADS-A. 26, 37, 38 Third, the specificity of the HADS-A and HADS-D are high (>90%) in IBD and RA at this threshold. 23, 25 Since the continuous HADS-A and HADS-D scores were highly correlated (r = 0.67), as expected, 24 dichotomizing these results also reduced the correlation (r = 0.31), allowing us to examine both variables in the same models.
Given that the normative databases available to obtain z scores for the cognitive domains adjusted for different demographic variables, we developed 2 sets of multivariate models. First, multivariate analyses of variance (MANOVAs) were conducted using disease cohort (all 4 cohorts), HADS-A dichotomized, and HADS-D dichotomized as the independent variables. Three cognitive domains were included as the dependent variables in this model: processing speed (SDMT), verbal learning (CVLT-II Trials 1-5), and verbal delayed recall memory (CVLT-II Delayed Recall). Combining correlated cognitive domains that used the same normative data reduced the number of comparisons and increased power. Since these z scores were adjusted for age, sex, and years of education, these variables were not included in the model. Second, analyses of covariance (ANCOVAs) were conducted with working memory (LNS) as the dependent variable. Disease cohort, sex, and years of education were included as independent variables because this z score was only adjusted for age. In both models, HADS-A dichotomized and HADS-D dichotomized were also included as independent variables. For each multivariate model, we also included interaction terms between disease cohort and HADS-A dichotomized, and disease cohort and HADS-D dichotomized, to examine whether the effects of anxiety and depression on cognition differed across the disease cohorts. Statistically significant associations identified in the MANOVA/ANCOVA were followed by pairwise comparisons using the Tukey-Kramer adjustment. Partial eta-squared (η 2 p ), which measures the proportion of variance explained after accounting for other independent variables, was reported as a measure of effect size, interpreted as small (0.01), medium (0.09), or large (0.25). 39 Next, we conducted complementary analyses. First, because our initial threshold for dichotomizing the HADS optimized specificity over sensitivity, we repeated the analyses using more liberal thresholds of 9 for anxiety and 8 for depression. 23, 26 Second, we repeated the analyses using SCID-based diagnoses of any anxiety disorder and of MDD rather than HADS-A and HADS-D scores. Third, recognizing that panic disorder is characterized by episodic symptoms (panic attacks) whereas the other anxiety disorders are not, we repeated these latter analyses after excluding panic disorder from the SCID-based definition of any anxiety disorder. Finally, we examined the joint effects of symptoms of anxiety or depression by substituting a categorical variable representing 4 groups: HADS-A < 11 and HADS-D < 11, HADS-A < 11 and HADS-D ≥ 11, HADS-A ≥ 11 and HADS-D < 11, and both HADS-A and HADS-D ≥ 11.
Assumptions of multivariate normality were tested using P-P and Q-Q plots. Homogeneity of variance and covariance was assessed using discriminant function analysis. We report the Pillai trace as it is relatively robust to departures from these assumptions. Equality of error variances across dependent variables was assessed using the Levene test for ANCOVAs. Statistical analyses were conducted using SPSS Statistics version 23 (IBM SPSS Statistics for Windows, Armonk, NY).
Data availability
Ethical approval precludes the data being used for another purpose or being provided to researchers who have not signed the appropriate confidentiality agreement, per the Bannatyne Health Research Ethics Board, University of Manitoba.
Results
Participants
We enrolled 964 participants (table 1) , who were predominantly female. Participants were generally highly educated, and the average age ranged from 43 to 59 years across cohorts. Although this was overall a midlife sample, younger and older individuals were represented in all cohorts. Participants were predominantly Caucasian. At the time of testing, 72.2% of the MS cohort was relapsing-remitting, 18.8% were secondary progressive, and 9.0% were primary progressive.
Anxiety and depression
As expected, the ANX/DEP cohort had the highest proportion of participants with current anxiety disorders as identified with the SCID (51.6%), followed by the IBD cohort (17.4%; . Symptom severity varied among individuals with current SCID-based diagnoses of an anxiety disorder or MDD. Among those with any anxiety disorder (n = 307), the mean (SD) HADS-A score was 11.8 (3.9), but 25% had scores <9, and 25% had scores of ≥15. Among those with current MDD (n = 150), the mean (SD) HADS-D score Figure 1 Proportion of participants cognitively impaired by domain Impairment was defined as a score less than or equal to 1.5 SD below the mean (z score ≤−1.5); the proportion of individuals that could be expected to fall 1.5 SD below the mean is represented by the dotted line; *significant at α = 0.05, **significant at α = 0.01, ***significant at α = 0.001.
e410 Neurology | Volume 92, Number 5 | January 29, 2019 Neurology.org/N was 10.8 (4.0), but 25% had scores <8, and 25% had scores of ≥14. Among the 607 participants without an anxiety disorder or MDD, the mean (SD) HADS-A score was 5.8 (3.8) and 25% had scores of ≥8, and the mean (SD) HADS-D score was 4.15 (3.4). Thus, reasonable concordance existed between the symptombased measures of anxiety and depression and the interviewbased diagnostic measures, but there were some differences.
Cognitive function
Participants differed little in their estimated premorbid IQ (WTAR), although the IBD cohort had slightly higher WTAR scores than the RA cohort (p = 0.026). Across the IMID cohorts, processing speed, verbal learning, and delayed recall memory were more commonly impaired (−1.5 SD below the mean or lower) and few participants (≤5.2%) had impaired working memory (figure 1). As expected, more persons in the MS cohort were impaired with respect to processing speed compared to the other 3 cohorts (table 2, p ≤ 0.001). The MS cohort also had the highest proportion of participants with impaired processing speed (30%), verbal learning (22%), and delayed recall memory (8%) (figure 1). Among participants in the MS cohort without clinically meaningful symptoms of either anxiety or depression (HADS-A and HADS-D < 11), impaired processing speed (26.6%), verbal learning (20.6%), and delayed recall memory (8.5%) were relatively common, although impaired working memory was not (3.0%).
When examining cognitive performance z scores, participants with MS performed worse than all other cohorts with respect to processing speed, falling approximately 1 SD below the other 2 IMID cohorts and the ANX/DEP cohort (table 2) . Participants with MS also performed worse than all other cohorts with respect to delayed recall memory. The MS cohort performed below the IBD and ANX/DEP cohort on working memory, and below the IBD and ANX/DEP cohorts on verbal learning. The other 3 cohorts differed from one another only with respect to processing speed; the ANX/DEP performed worse than the IBD and RA cohorts (table 2) .
Associations of anxiety and depression with cognition
In the MANOVA, the presence of clinically meaningful anxiety symptoms (HADS-A scores ≥11) was associated with cognitive test performance when adjusting for disease cohort (Pillai trace = 0.024, F 3,951 = 7.67, p < 0.0001; η In the ANCOVA with working memory as the dependent variable, clinically meaningful symptoms of anxiety were associated with reduced working memory (F 1,946 = 13.49, p < 0.001; η 2 p = 0.01) although symptoms of depression were not (p = 0.80). Working memory performance was lower in the MS and RA cohorts than in the IBD or ANX/DEP cohorts. We did not observe interactions between anxiety/depression symptoms and cognitive performance by disease cohort (figure 2).
Complementary analyses
When we repeated the MANCOVA analyses above, using a threshold of 9 to dichotomize the HADS-A and a threshold of 8 to dichotomize the HADS-D, symptoms of anxiety were again associated with cognitive function (Pillai trace = 0.023, F 3,951 = 7.48, p < 0.0001). Specifically, anxiety symptoms were associated with reduced processing speed (F 1,953 = 18.7, p < 0.0001; η 2 p = 0.02) and reduced verbal learning (F 1,953 = 7.14, p = 0.0077; n p 2 = 0.01). In this analysis, symptoms of depression were associated with cognitive function as well (Pillai trace = 0.0092, effects of depression or anxiety alone on cognition, whether we used the HADS threshold of 11 (figure 3A) or the lower thresholds (figure 3B), indicating no synergistic effects.
Discussion
We examined the association of current symptoms of anxiety and depression with cognitive function in MS as compared to 2 other IMID cohorts (IBD and RA) and in a non-IMID group with anxiety or depression (ANX/DEP). Based on the normal distribution, 7% of the population would be projected to meet criteria for impairment but these proportions were higher in the MS and the other study cohorts, particularly for the domains of processing speed and verbal learning. In the MS cohort, the observed pattern of cognitive impairments was consistent with previous demonstrations of impaired processing speed, verbal learning, and delayed recall memory in persons with MS. 5 We also observed differences in the cognitive test z scores, whereby the MS cohort performed worse (0.6-0.8 SDs) than the other IMID cohorts and the ANX/DEP cohort. Thus, the MS cohort did appear to experience lower cognitive functioning compared to the other disease cohorts, though not necessarily at a level that met a formal threshold for impairment. Previous studies have also reported deficits in processing speed in IBD, 30 and deficits in verbal memory in IBD and RA, in keeping with our findings.
12,31 Working memory was the only cognitive domain examined in the current study in which elevated rates of impairment were not seen. However, as previous studies have identified working memory as an affected cognitive domain in MS, IBD, and RA, [40] [41] [42] it is possible that the test of working memory that we employed lacks sensitivity for identifying impairment in these populations. Further studies with a broader range of working memory measures are clearly required.
Consistent with previous literature, we found that the prevalence of anxiety and depression in MS exceeded that expected for the general population, 3 and was similar to the other IMID cohorts. Across all disease cohorts, current symptoms of anxiety were associated with reduced cognitive functioning. Specifically, greater self-reported symptoms of anxiety were associated with slower processing speed, lower working memory performance, and reduced verbal learning, but not with delayed recall memory. Symptoms of depression were associated with cognition in complementary analyses, specifically with reduced processing speed. However, this was only seen when using a more liberal threshold for identifying individuals as having clinically meaningful symptoms, which doubled the number of those individuals with depression without anxiety symptoms and thereby enhanced our power to detect an effect. Similar findings to our main analyses were also reported in a recent study examining anxiety, depression, and stress in 322 persons with MS, in that only anxiety remained independently associated with cognitive function. 43 Neuroticism, which is associated with chronically elevated negative affect, has also been found to be associated with worse cognitive performance in MS. 44 Notably, the influence of anxiety on cognitive functioning did not differ across cohorts regardless of the cutpoints used to identify meaningful symptoms, or the use of SCID-based disorder criteria. This indicates that clinically meaningful symptoms of anxiety had effects on cognitive functioning that may contribute directly to the cognitive impairments identified for those with MS, as well as for those with other IMID including IBD and RA. Associations of anxiety symptoms with poorer cognitive functioning have also been reported previously in studies of otherwise healthy adults living with a psychiatric condition, 21 and these were evident in our ANX/ DEP cohort as well.
Most studies examining the effect of psychiatric symptoms on cognitive functioning in MS have focused on depression. Mild symptoms of depression have typically not been associated with problematic cognitive functioning, 9,45 although more severe depression has been associated with impaired working memory and information processing speed. 46 Most studies of MS have found depression to be associated with deficits on tests that place demands on information processing speed as well as more complex aspects of attentional control and working memory. 47, 48 In the general population, depression has been found to commonly affect working memory, a domain in which few participants were impaired in the current study, and to have broad effects on executive functioning, which was not specifically assessed herein. 21, 45 However, the challenges in disentangling the potential role of comorbid anxiety symptoms on cognitive functioning in those with MDD are recognized. 45 Moreover, clinically meaningful effects of anxiety symptoms (i.e., state anxiety) on processing efficiency and the control of attention by executive functions have been hypothesized as occurring in healthy populations. 46 In our study, clinically meaningful symptoms of anxiety were much more common than were symptoms of depression (30.2% vs 13.8% of the total sample), and relatively few participants had meaningful depressive symptoms in the absence of meaningful anxiety symptoms. These characteristics of our study sample may have influenced the limited associations that were detected with depression. However, given that anxiety and depression may have similar influences on cognitive functioning despite the differences in their presenting symptoms, and given that they are commonly comorbid, future studies will also need to examine both types of symptoms concurrently. It is also important to note that while the effect sizes were small in our cohorts, the observation that anxiety and depression symptoms remained associated with cognitive functioning after accounting for other established large-magnitude contributors, such as age and years of education, demonstrates that these symptoms are indeed important factors affecting cognitive function in MS, as well as in other populations with IMID. As depression and anxiety symptoms did not fully explain cognitive impairment in IBD and RA, further study of the reasons for this is warranted in these cohorts. Potential contributors include systemic or intestinal inflammation, 19 adverse treatment effects, and other comorbidities.
In all disease cohorts studied, a diagnosis of current anxiety disorder based on the SCID was associated with a decrease in cognitive performance but a diagnosis of MDD was not, based on our a priori analytic approach. This absence of an association with a diagnosis of MDD, despite the presence of an association with symptoms of depression, could reflect several factors. First, diagnoses of a disorder require a specific constellation of symptoms over a specific period of time, associated with some impairment of function. However, among those meeting diagnostic criteria, symptom severity can vary, as was seen in the variability in HADS scores that we observed among those with MDD and those with an anxiety disorder. Prior studies of individuals with MDD have reported that severity of symptoms is associated with the degree of cognitive impairment. 49 Thus, even those individuals who do not meet formal diagnostic criteria for a disorder may still experience elevated symptoms of anxiety or depression that interfere with cognitive functions.
Our study has important limitations. Although the characteristics of our IMID study participants are largely consistent with the epidemiology of these conditions, we noted a slightly greater female predominance than expected in all cohorts. 16 This may reflect an increased willingness of women to participate in research studies than men, 47 thereby reducing the generalizability of our findings. Women are at increased risk of depression and anxiety in the general population as well as in those with MS, IBD, and RA. 48 While sex-specific risks of cognitive impairment and sex-specific associations with symptoms of depression and anxiety may differ by disease, we did not pursue sex-specific analyses to explore effect modification by sex given the relatively small numbers of men in our study cohorts. Future studies specifically designed to address this issue may be needed. To reduce participant burden, cognitive assessments were limited to commercially available tests that could be readily administered in a clinic-type setting.
Relevant cognitive domains, such as executive functions, were not assessed and more demanding tests of working memory and complex attention were not included. Future studies using more complex cognitive tasks may detect differences between persons with MS and other IMID such as IBD and RA, and may also reveal differences in the effects of comorbid anxiety and depression on cognitive functions in persons with these conditions. Other factors that may influence cognition, such as use of psychotropic and immunomodulatory therapies, as well as measures of disease activity and specific disease phenotypes (which differ across cohorts), were also not included. The inclusion of healthy controls in future studies would also support analyses to determine whether there are synergistic effects of psychiatric disorders and IMID on cognition. Finally, our analyses employed only the initial assessment of a planned longitudinal study and these additional data should eventually allow for better causal inferences regarding the role of anxiety/depressive symptoms on cognitive performance in these populations.
Strengths of our study include the use of 2 IMID and one non-IMID cohort for comparison with our MS cohort. Our analyses were also based on both self-reported symptom severity of anxiety and depression as well as on diagnostic classification for current anxiety and depression disorder as established via the SCID-IV. 20 Although the range of cognitive domains assessed was limited, we examined multiple domains that are commonly affected in MS and other IMID and the proportions of cognitive impairments were considered in relation to base rates. Importantly, our analyses also allowed us to account for the presence of comorbid anxiety and depression, both at the level of symptom severity and disorder classification, when examining their effect on cognitive functioning.
We found that MS is associated with impairments in new learning, delayed recall memory, and processing speed and that impairment of information processing speed is more common in MS than other IMID populations. Anxiety disorders, and symptoms of anxiety and depression, were associated with reduced cognitive functioning in MS and these same associations were seen to a similar degree in those with IBD or RA, and in a cohort with psychiatric disorders without an IMID. While our ability to detect the effect of depression may have been limited, we found that greater self-reported symptoms of depression were associated with slower processing speed. Our findings suggest that in individuals with MS and other IMID in which anxiety and depression are common, and in individuals with a history of anxiety disorder or major depression, the severity of current anxiety and depression symptoms is more strongly associated with cognitive function than is a current formal diagnosis by DSM-IV criteria. Since symptoms of anxiety and depression represent potentially modifiable factors that influence the cognitive functioning of persons with MS and other populations, our findings highlight the importance of recognizing and managing these symptoms to mitigate their effect on the functioning of persons with these chronic conditions. 
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